China Target Of Major Investment Plans By Germany's Merck KGaA
This article was originally published in PharmAsia News
Executive SummaryChina is being targeted by German drug maker Merck KGaA for acquisitions of Chinese companies as it seeks to take advantage of a massive health-reform plan
You may also be interested in...
Biologic Exclusivity Provisions In USMCA Are Boon To Generics Industry; BIO Is 'Tremendously Worried'
Revised North American trade deal touted as enabling Congress to address crisis of high drug prices; requirement for 10 years biologic exclusivity is removed and language to allow incentives for generics added.
The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year.
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.